Adverse drug reactions of GLP-1 agonists: A systematic review of case reports

Shetty, Rashmi; Basheer, Fathima Thashreefa; Poojari, Pooja Gopal; Thunga, Girish; Chandran, Vijay; Acharya, Leelavathi D

doi:10.1016/j.dsx.2022.102427

Cited by 47 publications

(36 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To repurpose GLP-1RAs for future treatment of lung injury including asthma, COPD and others, attention should be made to their known and yet to be identified ADRs. As mentioned above, the most common ADR of GLP-1RAs is pancreatitis, demonstrated in certain animal model studies and clinical observations 82 , 83 . In conducting a recent clinical comparative study on asthma patients with GLP-1RAs versus other T2D drugs, Foer and colleagues 124 did not report the development of pancreatitis or other ADRs.…”

Section: Discussionmentioning

confidence: 87%

“…As a relatively novel category of T2D drugs, adverse drug reactions (ADRs) of GLP-1RAs have been intensively studied globally. As reviewed very recently by Shetty and colleagues, GLP-1RAs are most commonly associated with ADRs in the gastrointestinal tract, particularly pancreatitis 82 . Cardiovascular, renal, hematologic, dermatologic, neurologic, autoimmune, hepatic and metabolic associated ADRs were also identified for GLP-1RAs 82 .…”

Section: Glp-1r Agonists As Diabetes Drugsmentioning

confidence: 99%

“…As reviewed very recently by Shetty and colleagues, GLP-1RAs are most commonly associated with ADRs in the gastrointestinal tract, particularly pancreatitis 82 . Cardiovascular, renal, hematologic, dermatologic, neurologic, autoimmune, hepatic and metabolic associated ADRs were also identified for GLP-1RAs 82 . For more than a decade, the development of pancreatitis or even pancreatic cancer has been the major concern in utilizing GLP-1RAs.…”

Section: Glp-1r Agonists As Diabetes Drugsmentioning

confidence: 99%

“…He then concluded that although we should remain vigilant, the balance of evidence at current stage is in supporting GLP-1-based therapy strongly, with beneficial effects far outweighing those potential risks 83 . For further information on common and rare ADRs of GLP-1RAs, please see review articles elsewhere 82 , 84 , 85 , 86 .…”

Section: Glp-1r Agonists As Diabetes Drugsmentioning

confidence: 99%

See 3 more Smart Citations

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Pang

Feng

Ling

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 87%

Section: Glp-1r Agonists As Diabetes Drugsmentioning

confidence: 99%

Section: Glp-1r Agonists As Diabetes Drugsmentioning

confidence: 99%

Section: Glp-1r Agonists As Diabetes Drugsmentioning

confidence: 99%

See 2 more Smart Citations

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Pang

Feng

Ling

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“… 2 This class has a low side effect profile; however, acute kidney injury (AKI) requiring dialysis is listed as a possible rare adverse reaction (usually occurring in the setting of GLP-1RA induced nausea and vomiting with associated hypovolemia). 3 , 4 …”

mentioning

confidence: 99%

Semaglutide-Associated Acute Interstitial Nephritis: A Case Report

Borkum¹,

Lau²,

Blanco³

et al. 2022

Kidney Medicine

View full text Add to dashboard Cite

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review

Bianchi,

Ali Biglu Marash,

Malatesta

et al. 2023

JEADV Clinical Practice

View full text Add to dashboard Cite

Dulaglutide is a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, which stimulates insulin release via activation of GLP‐1 receptors on pancreatic beta cells. We report the case of a 45‐year‐old woman with type 2 diabetes mellitus who started dulaglutide subcutaneously and developed, a few minutes after the fourth administration, a persistent itchy reaction at the injection site, followed, after two more administrations, by a diffuse itchy delayed urticaria‐like rash, healed in 7 days after drug interruption. Skin test performed after 3 months from the event demonstrated the culprit role of the drug. Given the limited evidence in literature, there is currently no standardised protocol for testing patients sensitised to one or more glucagon‐like peptide‐1 receptor agonists. Performing skin tests, especially intradermal tests, is pivotal to confirm the aetiological role of the drug in the suspected hypersensitivity reaction, and possibly to identify an alternative to be proposed before precluding the entire drug class. To the best of our knowledge, this is the first case of systemic hypersensitivity reaction to dulaglutide presenting as a delayed urticaria‐like rash and confirmed by positive skin test.

show abstract

Adverse drug reactions of GLP-1 agonists: A systematic review of case reports

Cited by 47 publications

References 94 publications

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Semaglutide-Associated Acute Interstitial Nephritis: A Case Report

Hypersensitivity to glucagon‐like peptide‐1 receptor agonists: A case of delayed urticaria‐like rash to dulaglutide and literature review

Contact Info

Product

Resources

About